Liquidia (LQDA) Competitors

$53.13 +10.83 (+25.60%)

Closing price 04:00 PM Eastern

Extended Trading

$50.93 -2.20 (-4.14%)

As of 05:04 PM Eastern

LQDA vs. SNN, PEN, SOLV, GKOS, and BLCO

Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Smith & Nephew SNATS (SNN), Penumbra (PEN), Solventum (SOLV), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical equipment" industry.

How does Liquidia compare to Smith & Nephew SNATS?

Liquidia (NASDAQ:LQDA) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Liquidia currently has a consensus price target of $46.22, suggesting a potential downside of 12.92%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 6.22%. Given Smith & Nephew SNATS's higher possible upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

64.5% of Liquidia shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Liquidia had 15 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 22 mentions for Liquidia and 7 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.29 beat Liquidia's score of 0.24 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	29.80	-$68.92M	-$0.83	N/A
Smith & Nephew SNATS	$6.16B	2.02	$625M	N/A	N/A

Liquidia has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Smith & Nephew SNATS has a net margin of 0.00% compared to Liquidia's net margin of -43.53%. Smith & Nephew SNATS's return on equity of 0.00% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Smith & Nephew SNATS	N/A	N/A	N/A

Summary

Smith & Nephew SNATS beats Liquidia on 8 of the 15 factors compared between the two stocks.

How does Liquidia compare to Penumbra?

Liquidia (NASDAQ:LQDA) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Penumbra has a net margin of 11.76% compared to Liquidia's net margin of -43.53%. Penumbra's return on equity of 10.87% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Penumbra	11.76%	10.87%	8.45%

Liquidia currently has a consensus price target of $46.22, suggesting a potential downside of 12.92%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 12.34%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Liquidia had 11 more articles in the media than Penumbra. MarketBeat recorded 22 mentions for Liquidia and 11 mentions for Penumbra. Penumbra's average media sentiment score of 0.24 beat Liquidia's score of 0.24 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Penumbra	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	29.80	-$68.92M	-$0.83	N/A
Penumbra	$1.40B	9.01	$177.69M	$4.34	74.11

64.5% of Liquidia shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Liquidia has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Summary

Penumbra beats Liquidia on 11 of the 17 factors compared between the two stocks.

How does Liquidia compare to Solventum?

Liquidia (NASDAQ:LQDA) and Solventum (NYSE:SOLV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Solventum has a net margin of 17.33% compared to Liquidia's net margin of -43.53%. Solventum's return on equity of 23.51% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Solventum	17.33%	23.51%	7.63%

Liquidia currently has a consensus price target of $46.22, suggesting a potential downside of 12.92%. Solventum has a consensus price target of $85.91, suggesting a potential upside of 15.91%. Given Solventum's higher possible upside, analysts plainly believe Solventum is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Liquidia had 1 more articles in the media than Solventum. MarketBeat recorded 22 mentions for Liquidia and 21 mentions for Solventum. Solventum's average media sentiment score of 0.37 beat Liquidia's score of 0.24 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Solventum	2 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	29.80	-$68.92M	-$0.83	N/A
Solventum	$8.26B	1.55	$1.56B	$8.16	9.08

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Liquidia has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Solventum has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Summary

Solventum beats Liquidia on 10 of the 16 factors compared between the two stocks.

How does Liquidia compare to Glaukos?

Liquidia (NASDAQ:LQDA) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 6.4% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Glaukos has a net margin of -34.34% compared to Liquidia's net margin of -43.53%. Glaukos' return on equity of -6.92% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Glaukos	-34.34%	-6.92%	-5.25%

Liquidia presently has a consensus price target of $46.22, suggesting a potential downside of 12.92%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 6.84%. Given Glaukos' higher probable upside, analysts plainly believe Glaukos is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Liquidia had 9 more articles in the media than Glaukos. MarketBeat recorded 22 mentions for Liquidia and 13 mentions for Glaukos. Glaukos' average media sentiment score of 0.51 beat Liquidia's score of 0.24 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Liquidia has higher earnings, but lower revenue than Glaukos. Liquidia is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	29.80	-$68.92M	-$0.83	N/A
Glaukos	$507.44M	15.64	-$187.69M	-$3.28	N/A

Summary

Glaukos beats Liquidia on 10 of the 17 factors compared between the two stocks.

How does Liquidia compare to Bausch + Lomb?

Liquidia (NASDAQ:LQDA) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to Liquidia's net margin of -43.53%. Bausch + Lomb's return on equity of 3.60% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Bausch + Lomb	-4.21%	3.60%	1.69%

Liquidia presently has a consensus price target of $46.22, suggesting a potential downside of 12.92%. Bausch + Lomb has a consensus price target of $18.08, suggesting a potential upside of 12.32%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Liquidia had 10 more articles in the media than Bausch + Lomb. MarketBeat recorded 22 mentions for Liquidia and 12 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.20 beat Liquidia's score of 0.24 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bausch + Lomb	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Liquidia has higher earnings, but lower revenue than Bausch + Lomb. Liquidia is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	29.80	-$68.92M	-$0.83	N/A
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A

Summary

Bausch + Lomb beats Liquidia on 9 of the 17 factors compared between the two stocks.

Get Liquidia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LQDA vs. The Competition

Export

Metric	Liquidia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.72B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-63.95	15.19	20.66	25.69
Price / Sales	29.80	194.05	527.03	64.81
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	104.07	6.94	9.77	6.74
Net Income	-$68.92M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	37.69%	4.75%	6.33%	9.09%
1 Year Performance	246.46%	78.29%	41.88%	42.54%

Liquidia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LQDA Liquidia	2.0036 of 5 stars	$53.13 +25.6%	$46.22 -13.0%	+176.7%	$4.72B	$158.32M	N/A	50	Trending News Earnings Report Analyst Forecast Gap Up High Trading Volume
SNN Smith & Nephew SNATS	3.0197 of 5 stars	$30.92 -0.8%	$34.75 +12.4%	+5.6%	$13.30B	$6.16B	N/A	16,988	Analyst Downgrade
PEN Penumbra	2.7759 of 5 stars	$324.77 -0.2%	$364.60 +12.3%	+8.4%	$12.80B	$1.40B	71.85	4,700	Positive News Earnings Report Analyst Upgrade
SOLV Solventum	3.4771 of 5 stars	$67.52 +1.3%	$89.45 +32.5%	+4.4%	$11.55B	$8.33B	7.61	20,000	Earnings Report
GKOS Glaukos	2.0211 of 5 stars	$135.98 -3.0%	$138.85 +2.1%	+48.1%	$8.24B	$507.44M	N/A	1,094

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LQDA) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liquidia (LQDA) Competitors

LQDA vs. SNN, PEN, SOLV, GKOS, and BLCO

How does Liquidia compare to Smith & Nephew SNATS?

Summary

How does Liquidia compare to Penumbra?

Summary

How does Liquidia compare to Solventum?

Summary

How does Liquidia compare to Glaukos?

Summary

How does Liquidia compare to Bausch + Lomb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liquidia (LQDA) Competitors

LQDA vs. SNN, PEN, SOLV, GKOS, and BLCO

How does Liquidia compare to Smith & Nephew SNATS?

Do analysts prefer LQDA or SNN?

Do institutionals & insiders hold more shares of LQDA or SNN?

Does the media refer more to LQDA or SNN?

Which has higher valuation & earnings, LQDA or SNN?

Which has more risk and volatility, LQDA or SNN?

Is LQDA or SNN more profitable?

Summary

How does Liquidia compare to Penumbra?

Is LQDA or PEN more profitable?

Do analysts rate LQDA or PEN?

Does the media prefer LQDA or PEN?

Which has stronger valuation and earnings, LQDA or PEN?

Do insiders and institutionals hold more shares of LQDA or PEN?

Which has more volatility & risk, LQDA or PEN?

Summary

How does Liquidia compare to Solventum?

Is LQDA or SOLV more profitable?

Do analysts rate LQDA or SOLV?

Does the media prefer LQDA or SOLV?

Which has stronger valuation and earnings, LQDA or SOLV?

Do insiders and institutionals hold more shares of LQDA or SOLV?

Which has more volatility & risk, LQDA or SOLV?

Summary

How does Liquidia compare to Glaukos?

Do institutionals and insiders hold more shares of LQDA or GKOS?

Is LQDA or GKOS more profitable?

Do analysts rate LQDA or GKOS?

Does the media prefer LQDA or GKOS?

Which has more risk & volatility, LQDA or GKOS?

Which has higher valuation & earnings, LQDA or GKOS?

Summary

How does Liquidia compare to Bausch + Lomb?

Do institutionals and insiders hold more shares of LQDA or BLCO?

Is LQDA or BLCO more profitable?

Do analysts rate LQDA or BLCO?

Does the media prefer LQDA or BLCO?

Which has more risk & volatility, LQDA or BLCO?

Which has higher valuation & earnings, LQDA or BLCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools